Despite the megatrend of clean energy, the ICLN ETF has significantly underperformed, losing 48.5% since my initial sell rating in 2021. Valuations are now more attractive with an average forward ...
Humacyte's stock has dropped 29% since December, despite FDA approval of Symvess. Symvess faces slow adoption due to the need for long-term outcomes data. Humacyte's financial health is precarious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback